Skip to main content

Table 1 Summary of 21 cancers identified in 21 patients

From: Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer

Tumor number Histopathology Pathologic size (cm) Molecular subtype Assessment Tumor extent (cm) L/B ratio
99mTc sestamibi 99mTc maraciclatide 99mTc sestamibi 99mTc maraciclatide 99mTc sestamibi 99mTc maraciclatide
1 DCIS 7.0 Not applicable 4 4 10.3 8.3 1.54 1.79
2 IDC 0.6 Luminal 1 1 N/A N/A N/A N/A
3 IDC 0.7 Luminal 1 2 N/A N/A 1.02 1.15
4 IDC 0.8 Triple negative 3 4 1.2 1.1 1.16 1.15
5 IDC 0.9 Luminal 4 4 1.1 1.3 1.29 1.37
6 IDC 1.2 Luminal 4 4 3.1 3.1 1.59 1.71
7 IDC 1.5 HER-2 positive 4 5 1.5 1.3 1.62 1.60
8 IDC 1.6 HER-2 positive 5 4 2.1 1.7 1.93 2.70
9 IDC 1.7 Luminal 4 4 1.0 1.8 1.12 1.11
10 IDC 1.8 Triple negative 4 5 1.7 1.3 1.71 1.67
11 IDC 2.6 HER-2 positive 4 4 3.0 3.0 2.02 1.62
12 IDC 3.5 HER-2 positive 4 4 7.0 7.5 1.27 1.30
13 IDC 5.2 Luminal 4 4 3.0 3.3 1.57 1.50
14 IDC 5.4 Luminal 4 4 5.9 2.7 1.31 1.61
15 IDC 7.0 Luminal 5 4 3.0 3.0 1.63 1.79
16 IDC 9.2 Triple negative 4 4 11.0 9.2 1.43 1.42
17 Mixed IDC/ILC 1.1 Luminal 4 4 1.0 1.1 1.41 1.55
18 Mixed IDC/ILC 1.6 Luminal 4 4 6.5 6.3 1.68 1.68
19 Mixed IDC/ILC 3.7 Luminal 4 4 2.8 5.4 2.17 2.07
20 Mixed IDC/ILC 13.1 Luminal 5 5 11.4 12.5 2.31 2.09
21 ILC 2.5 Luminal 1 4 N/A 9.3 1.15 1.49
  1. DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma in situ